Grail, Inc. (NASDAQ:GRAL – Get Free Report) CFO Aaron Freidin sold 30,452 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $14.02, for a total value of $426,937.04. Following the transaction, the chief financial officer now owns 268,277 shares of the company’s stock, valued at approximately $3,761,243.54. The trade was a 10.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Grail Stock Performance
NASDAQ GRAL opened at $14.79 on Wednesday. Grail, Inc. has a 1 year low of $12.33 and a 1 year high of $23.36. The firm has a fifty day moving average price of $13.84.
Analyst Ratings Changes
GRAL has been the subject of several recent analyst reports. Wolfe Research initiated coverage on Grail in a research report on Friday, November 15th. They set a “peer perform” rating for the company. Guggenheim began coverage on Grail in a report on Thursday, October 17th. They set a “neutral” rating for the company.
Grail Company Profile
GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
Featured Stories
- Five stocks we like better than Grail
- Best Stocks Under $10.00
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- What is a Dividend King?
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.
